Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewAtipamezole hydrochloride is a selective α2-adrenergic receptor antagonist (Ki values are 1.1, 1.0, 0.89, 1300 and 6500 nM for α2A, α2B, α2C, α1A and α1B receptors respectively). Brain penetrant.
Atipamezole hydrochloride is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.
M. Wt | 248.75 |
Formula | C14H16N2.HCl |
Storage | Desiccate at RT |
Purity | ≥99% (HPLC) |
CAS Number | 104075-48-1 |
PubChem ID | 13649426 |
InChI Key | PCCVCJAQMHDWJY-UHFFFAOYSA-N |
Smiles | CCC2(C3=CN=CN3)CC1=CC=CC=C1C2.Cl |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
water | 24.87 | 100 | |
DMSO | 24.87 | 100 |
The following data is based on the product molecular weight 248.75. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 4.02 mL | 20.1 mL | 40.2 mL |
5 mM | 0.8 mL | 4.02 mL | 8.04 mL |
10 mM | 0.4 mL | 2.01 mL | 4.02 mL |
50 mM | 0.08 mL | 0.4 mL | 0.8 mL |
References are publications that support the biological activity of the product.
Virtanen et al (1989) Highly selective and specific antagonism of central and peripheral alpha 2-adrenoceptors by atipamezole. Arch.Int.Pharmacodyn.Ther. 297 190 PMID: 2567152
Puurunen et al (2001) An α2-adrenergic antagonist, atipamezole, facilitates behavioral recovery after focal cerebral ischemia in rats. Neuropharmacology 40 597 PMID: 11249969
Jurgens et al (2007) α2A adrenergic receptor activation inhibits epileptiform activity in the rat hippocampal CA3 region. Mol.Pharmacol. 71 1572 PMID: 17341653
If you know of a relevant reference for Atipamezole hydrochloride, please let us know.
Keywords: Atipamezole hydrochloride, Atipamezole hydrochloride supplier, selective, a-adrenergic, alpha-adrenergic, α-adrenergic, antagonists, receptors, alpha-adrenoceptors, a-adrenoceptors, αadrenoceptors, Adrenergic, Alpha-2, Receptors, 2937, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for Atipamezole hydrochloride include:
Hughes et al (2013) Endogenous analgesic action of the pontospinal noradrenergic system spatially restricts and temporally delays the progression of neuropathic pain following tibial nerve injury. Gastroenterology 154 1680 PMID: 23707289
Harris et al (2018) Dorsal BNST α2A-Adrenergic Receptors Produce HCN-Dependent Excitatory Actions That Initiate Anxiogenic Behaviors. J Neurosci 38 8922 PMID: 30150361
Do you know of a great paper that uses Atipamezole hydrochloride from Tocris? Please let us know.
Average Rating: 4 (Based on 1 Review.)
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
Behavioral neuropharmacology. Atimpamezole (0.1-1.0 mg/mL) was dissolved in 50-100% DMSO and was injected systemically in rats. Atipamezole is highly selective for the alpha2- noradrenergic receptor, and was used as a reference compound during behaviral testing.
This comes out of solution easily, even with sonicating. After fully dissolving in DMSO, add water slowly and continue to vortex or sonicate.
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.